From estrogen therapy to LHRH agonists;De l'oestrogénothérapie aux agonistes de la LHRH

Progres en Urologie

Volumn 17, Issue 2 SUPPL. 1, 2007, Pages 287-290

  Rossi, Dominique ^a   Cornu, Jean Nicolas ^a   Rouprêt, Morgan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; PROSTATECTOMY; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34447509470     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. CORBIN NS, THOMPSON I, JR. Urology and the Nobel Prize. Urol Oncol, 2003; 21: 83-5.
2. RICHAUD P, MOREAU JL, BEUZEBOC P, REBILLARD X, VILLERS A, PEYROMAURE M, et al. Suivi du cancer de la prostate. Recommandations du comité de cancérologie de l'Association Française d'Urologie. Prog Urol, 2005; 15: 586-92.
3. SOULIE M, BEUZEBOC P, IRANI J, DAVIN JL. Place actuelle de la chimiothérapie dans le traitement du cancer de la prostate hormonorésistant. Prog Urol, 2006; 16: 394-5.
4. BYAR DP. Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med, 1972; 48: 751-66.
5. HEDLUND PO, ALA-OPAS M, BREKKAN E, DAMBER JE, DAMBER L, HAGERMAN I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol, 2002; 36: 405-13.
6. KLOTZ L, MCNEILL I, FLESHNER N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol, 1999; 161: 169-72.
7. OCKRIM JL, LALANIEN, LANIADO ME, CARTER SS, ABEL PD. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol, 2003; 169: 1735-7.
8. SCHERR DS, PITTS WR, JR. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol, 2003; 170: 1703-8.
9. SEIDENFELD J, SAMSON DJ, HASSELBLAD V, ARONSON N, ALBERTSEN PC, BENNETT CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med, 2000; 132: 566-77.
10. PRICE D, STEIN B, SIEBER P, TUTRONE R, BAILEN J, GOLUBOFF E, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase HB clinical trial. J Urol, 2006; 176: 965-71.
11. SMITH MR. Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev Urol, 2005; 7 Suppl 3: S30-5.
12. DAVIN JL, CULINE S, SOULIE M, RAVERY V, ZERBIB M. Cancer de la prostate et atteinte ganglionnaire pelvienne: une maladie univoque? Prog Urol, 2006; 16: 239-56.
13. VILLERS A, HAFFNER J, TAIBI A, LUCAS C, WIBAULT P. Prise en charge thérapeutique de l'adénocarcinome de la prostate localement avancé en France. Enquête Observationnelle OCTAVE. Prog Urol, 2006; 16: 316-9.
14. RUFFION A, FONTAINE E, STAERMAN F. Traitement hormonal du cancer de la prostate métastatique. Prog Urol, 2003; 13: 334-41.
15. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol, 1997; 79: 235-46.
16. POUND CR, PARTIN AW, EISENBERGER MA, CHAN DW, PEARSON JD, WALSH PC. Natural history of progression after PSA elevation following radical prostatectomy. Jama, 1999; 281: 1591-7.
17. SEIDENFELD J, SAMSON DJ, ARONSON N, ALBERTSON PC, BAYOUMIAM, BENNETT C, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ), 1999: i-x, 1-246.
18. CHENG L, ZINCKE H, BLUTE ML, BERGSTRALH EJ, SCHERER B, BOSTWICK DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer, 2001; 91: 66-73.
19. CONROY T, MALISSARD L, DARTOIS D, LUPORSIE, STINES J, CHARDOT C. Histoire naturelle et évolution des métastases osseuses. Apropos de 429 observations. Bull Cancer, 1988; 75: 845-57.
20. MESSING EM, MANOLA J, SAROSDY M, WILDING G, CRAWFORD ED, TRUMP D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 1999; 341: 1781-8.
21. SGRIGNOLI AR, WALSH PC, STEINBERG GD, STEINER MS, EPSTEIN JI. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol, 1994; 152: 1077-81.
22. DANIELL HW. Osteoporosis after orchiectomy for prostate cancer. J Urol, 1997; 157: 439-44.
23. KARLING P, HAMMAR M, VARENHORST E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol, 1994; 152: 1170-3.
24. SCHRODER FH, COLLETTE L, DE REIJKE TM, WHELAN P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer, 2000; 82: 283-90.
25. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet, 2000; 355: 1491-8.
26. DE LA TAILLE A, ZERBIB M, CONQUY S, AMSELLEMOUAZANA D, THIOUNN N, FLAM TA, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int, 2003; 91: 18-22.
27. PETHER M, GOLDENBERG SL. Intermittent androgen suppression. BJU Int, 2004; 93: 258-61.
28. SCIARRAA, DICHIRO C, DI SILVERIO F. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol, 2000; 18: 392-400.
29. BOLLA M, VAN POPPEL H, COLLETTE L, VAN CANGH P, VEKEMANS K, DA POZZO L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet, 2005; 366: 572-8.
30. PILEPICH MV, WINTER K, LAWTON CA, KRISCH RE, WOLKOV HB, MOVSAS B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase IU RTOG 85-31. Int J Radiat Oncol Biol Phys, 2005; 61: 1285-90.
31. COLLETTE L, VAN POPPEL H, BOLLA M, VAN CANGH P, VEKEMANS K, DA POZZO L, et al. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer, 2005; 41: 2662-72.
32. JANOFF DM, PETERSON C, MONGOUE-TCHOKOTE S, PETERS L, BEER TM, WERSINGER EM, et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int, 2005; 96: 503-7.